Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2025Open Access

Early Use of Luspatercept After Allogeneic HSCT Improves Erythroid Recovery and Transfusion Burden

View Full Paper
Ask AI
Bookmark
Share

Authors

LWLing WangQingdao UniversitySJShiwei JinShanghai Jiao Tong UniversityMPMengmeng PanShanghai Jiao Tong University

Discussion

Loading...

Member takes

Implication

Retrospective cohort study found luspatercept improved hemoglobin levels in adults after allogeneic HSCT, suggesting better erythroid recovery and reduced transfusion burden.

Key Points

  • An 91.8% erythroid response was observed in patients treated with luspatercept after allo-HSCT, indicating improved recovery.
  • Luspatercept recipients had a greater increase in hemoglobin levels at one week, rising from 55 to 65 g/L.
  • In a retrospective cohort study, luspatercept reduced the need for RBC transfusion compared to controls, with only 10.2% requiring transfusion.
  • Findings suggest luspatercept may aid in managing anemia post-HSCT, but prospective trials are needed for confirmation.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69054ffa1a99e50463de69aahttps://doi.org/10.21203/rs.3.rs-7900872/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Abatacept improves posttransplant survival and reduces endothelial injury syndromes in β-thalassemia major2025 · 3 citations